SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 201.33 |
Enterprise Value ($M) | 186.86 |
Book Value ($M) | 14.83 |
Book Value / Share | 0.54 |
Price / Book | 13.58 |
NCAV ($M) | 6.56 |
NCAV / Share | 0.24 |
Price / NCAV | 30.69 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -2.68 |
Return on Assets (ROA) | -0.84 |
Return on Equity (ROE) | -2.02 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.15 |
Current Ratio | 4.15 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 55.74 |
Assets | 64.00 |
Liabilities | 49.18 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 3.50 |
Operating Income | -48.20 |
Net Income | -54.19 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -37.01 |
Cash from Investing | 0.21 |
Cash from Financing | 37.06 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | EcoR1 Capital, LLC | 4.20 | -39.13 | |
13G/A | Armistice Capital, Llc | 4.99 | 17.64 | |
13G/A | Point72 Asset Management, L.P. | 6.40 | 43.37 | |
13G/A | Nantahala Capital Management, LLC | 9.90 | 83.85 | |
13G/A | Flynn James E | 3.39 | -50.00 | |
13G/A | Integrated Core Strategies (us) Llc | 5.70 | 4.15 | |
13G/A | Adage Capital Partners Gp, L.l.c. | 15.32 | 144.15 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
40,987 | 127,763 | 32.08 | |
49,130 | 198,622 | 24.74 | |
39,578 | 167,610 | 23.61 | |
27,040 | 171,596 | 15.76 | |
(click for more detail) |
Similar Companies | |
---|---|
AADI – Aadi Bioscience, Inc. | ABIO – ARCA biopharma, Inc. |
ABVC – ABVC BioPharma, Inc. |